Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo

Vaccine

Volumn 15, Issue 4, 1997, Pages 441-448

  Del Guercio, Marie France ^a   Alexander, Jeff ^a   Kubo, Ralph T ^a   Arrhenius, Thomas ^a   Maewal, Ajesh ^a   Appella, Ettore ^b   Hoffman, Stephen L ^c   Jones, Trevor ^c   Valmori, Danila ^a   Sakaguchi, Kazuyasu ^b   Grey, Howard M ^d   Sette, Alessandro ^a  

^a CYTEL CORPORATION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

humoral immunity; malaria; PAN DR T helper epitopes; peptide based vaccine; short linear peptide

Indexed keywords

EPITOPE; MALARIA VACCINE; SYNTHETIC PEPTIDE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030955428     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00186-2     Document Type: Article

References (37)

1. Nardelli, B. and Tam, J.P. The MAP system: A flexible and unambiguous vaccine design of branched peptides. In: Vaccine Design: The Subunit and Adjuvant Approach (Eds Powell, M.F. and Newman, M.J.). Plenum Press, New York, 1995, pp. 803-816
2. Nardin, E.H., Oliveira, G.A., Calvo-Calle, J.M. and Nussenzweig, R.S. The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Adv. Immun. 1995, 60, 105-149
3. Chesnut, R. W., Sette, A., Cells, E. et al. Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. In Vaccine Design: The Subunit and Adjuvant Approach (Eds Powell, M.F. and Newman, M.J.). Plenum Press, New York, 1995, pp. 847-867
4. Cells, E., Sette, A. and Grey, H.M. Epitope selection and development of peptide based vaccines to treat cancer. Cancer Biol. 1995, 6, 329-336
5. Lanzavecchia, A. Identifying strategies for immune intervention. Science 1993, 260, 937-944
6. Alexander, J., Sidney, J. and Southwood, S. et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994, 1, 751-761
7. Cambier, J.C., Pleiman, C.M. and Clark, M.R. Signal transduction by the B cell antigen receptor and its coreceptors. A. Rev. Immun. 1994, 12, 457-486
8. Clark, E.A. and Lane, P.J.L. Regulation of human B-cell activation and adhesion. A. Rev. Immun. 1991, 9, 97-127
9. Vitiello, A., Ishioka, G. and Grey, H.M. et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J. Clin. Invest. 1995, 95, 341-349
10. Panina-Bordignon, P., Tan, A. and Termijtelen, A. et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immun. 1989, 19, 2237-2242
11. McCutchan, T.F., Altaf, A.L. and de la Cruz, V.F. et al. Sequence of the immunodominant epitope of the surface protein on sporozoites of Plasmodium vivax. Science 1985, 230, 1381
12. Potocnjak, P., Yoshida, N., Nussenzweig, R.S. and Nussenzweig, V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malaria infection. J. Exp. Med. 1980, 151, 1504-1513
13. Charoenvit, Y., Mellouk, S. and Cole, C. et al. Monoclonal, but not polyclonal antibodies protect against Plasmodium yoelii sporozoites. J. Immun. 1991, 146, 1020-1025
14. Ballou, W.R., Hoffman, S.L., Sherwood, J.A. et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987, 1277-1281
15. Herrington, D.A., Clyde, D.F. and Losonsky, G. et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987, 328, 257-259
16. Hoffman, S.L., Edelman, L.R. and Bryan, J. et al. Safety, immunogenicity and efficacy of a malaria spozoroite vaccine administered with monophosphoryl lipid A cell wall skeleton of mycobacteria and squalene. Am. J. Trop. Med. Hyg. 1994, 51, 603
17. Alving, C.R., Verma, J.N. and Rao, U. et al. Liposomes containing lipid A as a potent non-toxic adjuvant. Res. Immun. 1992, 143, 197-198
18. Alving, C.R. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 1993, 187, 430-446
19. Tarn, J.P., Clavijo, P., Lu, Y. and Nussenzweig, V. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 1990, 171, 299-306
20. Zavala, F., Tarn, J.P. and Barr, P.J. et al. Synthetic peptide vaccine confers protection against malaria. J. Exp. Med. 1987, 166, 1591-1596
21. Zavala, F., Romero, P.J., Ley, V. et al. Synthetic peptide vaccine against murine malaria. In: Vaccines (Eds Ginsberg, H., Brown, F., Lerner, R.A. and Chanock, R.M.). CSH Press, New York, 1988, p.61
22. Wang, R., Charoenvit, Y. and Corradin, C. et al. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immun. 1995, 154, 2784-2793
23. Romero, P., Heimer, E.P. and Herrera, S. et al. Antigenic analysis of the repeat domain of the circumspozoroite protein of Plasmodium vivax. J. Immun. 1987, 139, 1679-1682
24. Nussenzweig, V. and Nussenzweig, R.S. Rationale for the development of an engineered spozoroite malaria vaccine. Adv. Immun. 1989, 45, 283-334
25. Nardin, E.H., Barr, P.J., Heimer, E. and Etlinger, H.M. Genetic restriction of the murine humoral response to a recombinant Plasmodium vivax circumsporozoite protein. Eur. J. Immun. 1988, 18, 1119-1122
26. Buus, S., Sette, A., Colon, S.M., Miles, C. and Grey, H.M. The relation between major histocornpatibility complex (MHC) restriction and the capacity of la to bind immunogenic peptides. Science 1987, 235, 1353-1358
27. Dame, J.B., Williams, J.L. and McCutchan, T.F. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984, 225, 593-599
28. de Oliveira, G.A., Clavijo, P., Nussenzweig, R.S. and Nardin, E.H. Immunogenicity of an Alum-absorbed synthetic multiple-antigen peptide based on B-and T-cell epitopes of the Plasmodium falciparum CS protein: possible application. Vaccine 1994, 11, 1012-1017
29. Charoenvit, Y., Leef, M.F., Yuan, L.F., Sedegah, M. and Beaudoin, R.L. Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infect. Immun. 1987, 55, 604-608
30. Calvo-Calle, J.M., de Oliveira, G.A. and Clavijo, P. et al. Immunogenicity of multiple antigen peptides containing B and non-repeat T cell epitopes of the circumsporozoite protein of Plasmodium falciparum. J. Immun. 1993, 150, 1403-1412
31. DiJohn, D., Tores J.R., Murillo, J. et al. Effect of priming with carrier on response to conjugate vaccine. The Lancet 1989, 1415-1418
32. Frenchick, P., Sabara, M.I., Ijaz, M.K. and Babiuk, L.A. Immune responses to synthetic peptide vaccines of veterinary importance. Appl. Virol. Res. 1988, 1, 141-146
33. Etlinger, H.M., Gillessen, D. and Lahm, H.W. et al. Use of prior vaccinations for the development of new vaccines. Science 1990, 249, 423-425
34. Ijaz, M.K., Alkarmi, T.O. and El-Mekki, A.W. et al. Priming and induction of anti-rotavirus antibody response by synthetic peptides derived from VP7 and VP4. Vaccine 1995, 13, 331-338
35. Deefort, J.P., Nardelli, B., Huang, W.H. and Tarn, J.P. A rational design of synthetic peptide vaccine with a built in adjuvant: A molecular approach for ambiguity. Int. J. Peptide Protein Res. 1992, 40, 214-221
36. Wrotnowski, C. Multiple antigenic peptides: Arming biotech research and development. Editorial. Genetic Engng News 1 November 1995
37. Briand, J., Barin, C., Van Regenmortel, M. and Muller, S. Application and limitations of the multiple antigen peptide (MAP) system in the production and evaluation of anti-peptide and anti-protein antibodies. J. Immun. Meth. 1992, 156, 255-265